Humanized anti-CD134 (OX40) antibodies and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9790281
SERIAL NO

14221212

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BIOCEROX PRODUCTS B V1328 GJ ALMERE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Boon, Louis Almere, NL 14 121
Brezski, Randall Spring House, US 11 105
Goldberg, Monica Spring House, US 3 60
Luo, Jinquan Spring House, US 75 607
Simons, Petrus Johannes Almere, NL 11 112

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 17, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 17, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00